Organovo Holdings, Inc. (ONVO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONVO Stock Summary
- The ratio of debt to operating expenses for Organovo Holdings Inc is higher than it is for about merely 0.55% of US stocks.
- With a year-over-year growth in debt of -100%, Organovo Holdings Inc's debt growth rate surpasses merely 0% of about US stocks.
- Revenue growth over the past 12 months for Organovo Holdings Inc comes in at -91.12%, a number that bests merely 1.26% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Organovo Holdings Inc are GRIL, RDVT, FN, DHIL, and AQMS.
- ONVO's SEC filings can be seen here. And to visit Organovo Holdings Inc's official web site, go to www.organovo.com.
ONVO Stock Price Chart Interactive Chart >
ONVO Price/Volume Stats
|Current price||$2.79||52-week high||$23.92|
|Prev. close||$2.90||52-week low||$2.71|
|Day high||$3.01||Avg. volume||71,957|
|50-day MA||$4.30||Dividend yield||N/A|
|200-day MA||$6.80||Market Cap||24.29M|
Organovo Holdings, Inc. (ONVO) Company Bio
Organovo Holdings, Inc. focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company was founded in 2007 and is based in San Diego, California.
Most Popular Stories View All
ONVO Latest News Stream
|Loading, please wait...|
ONVO Latest Social Stream
View Full ONVO Social Stream
Latest ONVO News From Around the Web
Below are the latest news stories about Organovo Holdings Inc that investors may wish to consider to help them evaluate ONVO as an investment opportunity.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today released its first detailed response to the lawsuit Cellink (NASDAQ Stockholm: BICO) filed against it in Delaware court in 2021. At issue in this lawsuit is whether Cellink is infringing Organovo patents. Organovo, as one of the earliest and most prominent 3D bioprinting companies, has built a strong and foundational patent portfolio in the space. Organovo believes that Cellink, as a newer company with lim
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Global 4D Printing In Healthcare Market: Emerging Trends, Major Key Players 3D Systems, Inc and Organovo Holdings Inc
According to the report, The global 4D Printing in the Healthcare market size is expected to reach $50.76 Billion by 2028 growing at the CAGR of 27.71% from 2021 to 2028. The major driver for the 4D printing industry in
Credit Suisse AG acquired a new position in shares of Organovo Holdings, Inc. (NASDAQ:ONVO) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 15,607 shares of the medical research companys stock, valued at approximately $147,000. Credit Suisse AG owned 0.18% of Organovo at the end 
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and other 3D tissue technologies.
ONVO Price Returns